Search | Page 16 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Britta Will, PhD

    ... the only curative option for MDS. Even though 5- azacitidine (5-aza) has resulted in clinical responses and improvements in ...

    Grant Recipient last updated 07/07/2016 - 9:46am.

  2. Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS

    ... Phase II trial combining azacitidine with valproic acid as maintenance therapy post allogeneic stem ... MDS/AML. We hypothesize that adding valproic acid to azacitidine will improve outcomes via both direct anti-tumor and ... is near 40%. We hypothesize that valproic acid and azacitidine will prolong survival, with a 1 year survival goal of 60%. In ...

    Clinical Trial last updated 04/29/2016 - 12:35pm.

  3. Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)

    ... Opdivo (nivolumab), alone or in combination with Vidaza ( azacitidine ), can help to control MDS. The safety of these drug ... Associated Drug(s):  Azacitidine Phase:  Phase 2 ...

    Clinical Trial last updated 04/29/2016 - 11:16am.

  4. Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS)

    ... to learn if nivolumab and/or ipilimumab, with or without azacitidine , are safe to give to patients with MDS. Researchers also want ... Associated Drug(s):  Azacitidine Phase:  Phase 2 ...

    Clinical Trial last updated 04/28/2016 - 2:01pm.

  5. Phase 1 Study to Evaluate MEDI4736 in MDS

    ... of MEDI4736 monotherapy and MEDI4736 in combination with azacitidine in adult patients with myelodysplastic syndrome. ... Associated Drug(s):  Azacitidine Phase:  Phase 1 ...

    Clinical Trial last updated 04/27/2016 - 12:43pm.

  6. Clinical Trials Report for April 2016

    ... failure of treatment with a hypomethylating agent (HMA), azacitidine (AZA) or decitabine (DEC). This study is ...

    Page last updated 08/10/2016 - 11:00am.

  7. New therapeutics for myelodysplastic syndromes

    ... lenalidomide (Revlimidâ) and the azanucleosides, azacitidine (Vidazaâ) and decitabine (Dacogenâ).  Although these ... Targeting the MDS clone:   The azanucleosides (azacitidine and decitabine) remain the best treatment option for many ...

    Research Review last updated 05/02/2016 - 9:28am.

  8. A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML)

    ... leukemia (AML). Two study drugs will be tested: 5AC (5- azacitidine ) and entinostat. 5AC improves blood counts in 50 - 60% of ... 10 Other Name: MS275 Drug: 5AC Other Name: 5-azacitidine Drug: Entinostat days 10,17 Given orally on days 10, 17 ...

    Clinical Trial last updated 06/03/2016 - 3:09pm.

  9. Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation

    ... of this clinical research study is to learn if 5- azacitidine and sorafenib can help to control the disease in patients with ... Associated Drug(s):  Azacitidine Phase:  Phase 2 ...

    Clinical Trial last updated 04/29/2016 - 12:23pm.

  10. More is better: Combination therapies for myelodysplastic syndromes

    ... FDA-approved medications for MDS: lenalidomide , azacitidine , and decitabine .  Although these agents can be ... therapy is using an epigenetic approach, where one combines azacitidine or decitabine (the class of drugs known as hypomethylating agents) ...

    Research Review last updated 05/02/2016 - 9:14am.